Balyasny Asset Management LLC Acadia Pharmaceuticals Inc Call Options Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	BUY	$16.61 - $20.29 $1.66 Million - $2.03 Million	100,000 New	100,000 $1.66 Million
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $2.92 Million - $3.68 Million	200,000 New	200,000 $3.25 Million
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $2.08 Million - $3.18 Million	100,000 New	100,000 $3.13 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $6.16 Million - $8.52 Million	-150,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$36.42 - $57.0 $3.46 Million - $5.42 Million	95,000 Added 172.73%	150,000 $6.19 Million
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $716,650 - $1.2 Million	55,000 New	55,000 $831,000

356

163M

1.77M

307K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.73B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.